RiverVest Venture Partners

SeQure Dx Announces $17.5M Series A Funding

Retrieved on: 
Tuesday, August 3, 2021
Professional services, Health, Genetics, Finance, Research, Science, DX, RiverVest Venture Partners, Mass General Brigham Ventures, RIVERVEST VENTURE PARTNERS, MASS GENERAL BRIGHAM VENTURES

SeQure Dx , a gene-editing diagnostics company, announced today a $17.5 million Series A funding led by RiverVest Venture Partners and Mass General Brigham Ventures along with Digitalis Ventures, Casdin Capital, KdT Ventures, Bold Capital Partners and Alexandria Venture Investments.

Key Points: 
  • SeQure Dx , a gene-editing diagnostics company, announced today a $17.5 million Series A funding led by RiverVest Venture Partners and Mass General Brigham Ventures along with Digitalis Ventures, Casdin Capital, KdT Ventures, Bold Capital Partners and Alexandria Venture Investments.
  • SeQure Dx was founded on exclusive licensure of GUIDE-seq, ONE-seq and related assay technologies for detection of off-target gene-editing events.
  • Dr. Joung is a scientific founder of SeQure Dx and chair of the companys Scientific Advisory Board.
  • SeQure Dx is uniquely positioned to aid gene-editing innovators in providing safe patient access to novel treatments, and we are pleased to support SeQure Dx through this accelerated growth period.

Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease

Retrieved on: 
Wednesday, June 23, 2021
Professional services, Health, Finance, Clinical trials, Pharmaceutical, Biotechnology, Congenital disorders of glycosylation, PMM2, Genetic genealogy, Medical genetics, Branches of biology, Novo Holdings A/S, CDG, PMM2-CDG, Glycomine, Inc., Abingworth, Sanofi Ventures, RiverVest Venture Partners, Remiges Ventures, PMM2-CDG, GLYCOMINE, INC., ABINGWORTH, SANOFI VENTURES, RIVERVEST VENTURE PARTNERS, REMIGES VENTURES

The proceeds of the financing will be used to advance Glycomines lead drug candidate, GLM101, through initial clinical trials in patients.

Key Points: 
  • The proceeds of the financing will be used to advance Glycomines lead drug candidate, GLM101, through initial clinical trials in patients.
  • GLM101 is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
  • The Series B financing includes $35 million of new funds in addition to the $33 million announced in August 2019.
  • In addition, all previous Series B investors Novo Holdings A/S, Asahi Kasei Pharma Ventures, Mission BioCapital, Sanderling Ventures, and Chiesi Ventures participated.